Vernalis PLC Vernalis Results of Annual General Meeting (7260Q)
02 December 2016 - 12:00AM
UK Regulatory
TIDMVER
RNS Number : 7260Q
Vernalis PLC
01 December 2016
1 December 2016
LSE: VER
Vernalis Results of Annual General Meeting
Resolutions
Vernalis plc (LSE: VER) announces that all resolutions proposed
to shareholders at its Annual General Meeting held today were duly
passed.
All resolutions were approved on a show of hands. The number of
proxy votes received for each resolution is set out below.
For (including
discretionary
Resolution votes)* Against* Withheld
-------------------------------- ---------------------- ------------------- ----------
Ordinary Resolutions (requires 50% majority)
-----------------------------------------------------------------------------------------
1. That the audited
accounts and related
reports of the directors
and auditors for the
12 month period ended (>99.99 (<0.01
30 June 2016 be received 481,517,407 %) 1,302 %) 178
-------------------------------- ------------ -------- ---------- ------- ----------
2. That the remuneration
report contained within
the report and accounts
for the 12 month period
ended 30 June 2016 (>98.62 (<1.38
be approved 474,876,956 %) 6,639,291 %) 2,640
-------------------------------- ------------ -------- ---------- ------- ----------
3. That Dr Fellner
be re-elected as a (>99.99 (<0.01
director 479,611,759 %) 26,936 %) 1,880,192
-------------------------------- ------------ -------- ---------- ------- ----------
4. That Ms Ferguson
be re-elected as a (<99.61 (>0.39
director 479,635,151 %) 1,883,550 %) 186
-------------------------------- ------------ -------- ---------- ------- ----------
5. That Mr Mackney
be re-elected as a (>99.99 (<0.01
director 481,514,918 %) 3,708 %) 261
-------------------------------- ------------ -------- ---------- ------- ----------
6. That PricewaterhouseCoopers
LLP be reappointed
auditors and the directors
be authorised to determine (>98.62 (<1.38
their remuneration 474,881,144 %) 6,637,552 %) 191
-------------------------------- ------------ -------- ---------- ------- ----------
7. That the directors
be authorised to allot (>99.99 (<0.01
shares 479,617,975 %) 19,306 %) 1,881,606
-------------------------------- ------------ -------- ---------- ------- ----------
Special Resolutions (requires 75% majority)
-----------------------------------------------------------------------------------------
8. That the directors
be authorised to disapply (>99.99 (<0.01
pre-emption rights 481,478,371 %) 36,956 %) 3,560
-------------------------------- ------------ -------- ---------- ------- ----------
9. That the directors
be authorised to disapply
pre-emption rights
in connection with
an acquisition or specified (>99.60 (<0.40
capital investment 479,598,409 %) 1,916,786 %) 3,692
-------------------------------- ------------ -------- ---------- ------- ----------
*NB: A vote withheld is not a vote in law and, is not counted in
the calculation of the votes for or against a resolution.
Therefore, the percentage of votes cast excludes withheld votes
On 1 December 2016, there were 526,352,521 Vernalis plc ordinary
shares in issue. Shareholders are entitled to one vote per share
held.
The full text of each resolution passed at the Annual General
Meeting held earlier today, Thursday 1 December 2016, is set out in
the Notice of Annual General Meeting which is available for viewing
on the Company's website at www.vernalis.com.
-- ends -
Enquiries:
Vernalis: +44 (0) 118 938 0015
Ian Garland, Chief Executive Officer
David Mackney, Chief Financial Officer
Canaccord Genuity Limited (Nominated
Adviser and Joint Broker): +44 (0) 20 7523 8350
Dr Julian Feneley
Henry Fitzgerald-O'Connor
Rupert Winkler
Emma Gabriel
Shore Capital (Joint Broker): +44 (0)20 7408 4090
Bidhi Bhoma
Toby Gibbs
FTI Consulting: +44 (0) 20 3727 1000
Ben Atwell
Simon Conway
Stephanie Cuthbert
Notes to Editors
About Vernalis
Vernalis is a revenue generating, commercial stage
pharmaceutical company with significant expertise in drug
development. The Group has three approved products: Tuzistra(R) XR
targeting the US prescription cough-cold market; Moxatag(R), a
once-a-day formulation of the antibiotic, amoxicillin, indicated
for the treatment of tonsillitis and/or pharyngitis secondary to
Streptococcus pyogenes in adults and pediatric patients 12 years
and older; and frovatriptan for the acute treatment of migraine. It
has an exclusive licensing agreement to develop and commercialise
multiple novel products focussed on the US prescription cough-cold
market as well as eight programmes in its NCE development pipeline.
Vernalis has also significant expertise in fragment and structure
based drug discovery which it leverages to enter into
collaborations with larger pharmaceutical companies. The Company's
technologies, capabilities and products have been endorsed over the
last five years by collaborations with leading pharmaceutical
companies, including Asahi Kasei Pharma, Biogen Idec, Endo, GSK,
Genentech, Lundbeck, Menarini, Novartis, Servier, Taisho, and
Tris.
For further information about Vernalis, please visit
www.vernalis.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
RAGLLFEFFALLIIR
(END) Dow Jones Newswires
December 01, 2016 08:00 ET (13:00 GMT)
Vernalis (LSE:VER)
Historical Stock Chart
From Apr 2024 to May 2024
Vernalis (LSE:VER)
Historical Stock Chart
From May 2023 to May 2024